摘要
目的分析格列美脲和格列吡嗪治疗2型糖尿病的效果和价值。方法回顾性分析该院2020年3月—2021年7月收治的60例2型糖尿病患者,并随机分为对照组和观察组,每组30例,对照组采用格列吡嗪治疗,观察组采用格列美脲治疗;比较两组临床疗效、不良反应发生率以及治疗前后患者血糖、血脂水平和体质量改善情况。结果观察组临床疗效为96.67%,不良反应发生率为6.67%,对照组分别为76.67%、26.67%,两组比较,差异有统计学意义(P<0.05)。观察组,患者血糖各指标水平较低,血脂水平改善幅度较大,体质量、体质指数及体脂百分比下降幅度较大,差异有统计学意义(P<0.05)。结论与格列吡嗪相比,格列美脲在2型糖尿病的治疗中更具优势,可提升临床疗效并改善患者预后。
Objective To analyze the effect and value of glimepiride and glipizide in the treatment of type 2 diabetes.Methods A retrospective analysis of 60 patients with type 2 diabetes mellitus in the hospital from March 2020 to July 2021 was selected and randomly divided into a control group and an observation group,30 cases in each group,the control group was treated with glipizide,and the observation group was treated with glipizide urea treatment;the clinical efficacy,incidence of adverse reactions,blood glucose,blood lipid levels,and body weight improvement before and after treatment were compared between the two groups.Results The clinical efficacy of the observation group was 96.67%,and the incidence of adverse reactions was 6.67%,while those of the control group were 76.67%and 26.67%,respectively,and the difference between the two groups was statistically significant(P<0.05).In the observation group,the blood glucose levels of the patients were lower,the blood lipid levels improved significantly,and the body mass,body mass index and body fat percentage decreased significantly,and the difference was statistically significant(P<0.05).Conclusion Compared with glipizide,glimepiride has more advantages in the treatment of type 2 diabetes,which can improve the clinical efficacy and improve the prognosis of patients.
作者
熊小芹
冯潇宇
毛爱珺
马丁
XIONG Xiaoqin;FENG Xiaoyu;MAO Aijun;MA Ding(Department of Endocrinology,Bazhong Central Hospital,Bazhong,Sichuan Province,636000 China)
出处
《糖尿病新世界》
2022年第7期75-78,共4页
Diabetes New World Magazine
关键词
格列美脲
格列吡嗪
2型糖尿病
不良反应
血糖
血脂
Glimepiride
Glipizide
Type 2 diabetes
Adverse reactions
Blood glucose
Blood lipids
